Amphastar Pharmaceuticals
AMPH
116 hedge funds and large institutions have $296M invested in Amphastar Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 49 increasing their positions, 40 reducing their positions, and 28 closing their positions.
23% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 40
4.06% less ownership
Funds ownership: 48.56% → 44.49% (-4.1%)
16% less funds holding
Funds holding: 138 → 116 (-22)
28% less capital invested
Capital invested by funds: $412M → $296M (-$116M)
31% less call options, than puts
Call options by funds: $286K | Put options by funds: $416K
57% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$86.7M |
| 2 |
RCAMU
Rothschild & Co Asset Management US
Stamford,
Connecticut
|
+$9.82M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$5.3M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4.09M |
| 5 |
State Street
Boston,
Massachusetts
|
+$1.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$15.9M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$14.6M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$4.71M |
| 4 |
Prudential Financial
Newark,
New Jersey
|
-$4.11M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
-$3.19M |
AMPH Hedge Fund Activity: Q1 2017 in Review
116 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q1 2017, worth a combined $296M — down 28% from $412M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of AMPH and 12 opened new positions — a net loss of 16 holders — while 40 trimmed existing stakes and 49 added.
The largest buyer was BlackRock, adding an estimated $86.7M. The largest seller was Fidelity Investments, cutting an estimated $15.9M.
- 116 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q1 2017, down from 138 in Q4 2016.
- Funds reported $296M of Amphastar Pharmaceuticals stock for Q1 2017, down 28% quarter-over-quarter.
- 12 funds opened new Amphastar Pharmaceuticals positions in Q1 2017 and 28 closed out, a net change of -16 holders.
- The largest Amphastar Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $86.7M added.
- The largest Amphastar Pharmaceuticals seller in Q1 2017 was Fidelity Investments, an estimated $15.9M sold.
Based on aggregated 13F filings for Q1 2017.